-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Reviewing Aurinia Pharmaceuticals (NASDAQ:AUPH) & Tango Therapeutics (NASDAQ:TNGX)
Reviewing Aurinia Pharmaceuticals (NASDAQ:AUPH) & Tango Therapeutics (NASDAQ:TNGX)
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) and Tango Therapeutics (NASDAQ:TNGX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.
Earnings & Valuation
This table compares Aurinia Pharmaceuticals and Tango Therapeutics' top-line revenue, earnings per share and valuation.
Get Aurinia Pharmaceuticals alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aurinia Pharmaceuticals | $45.60 million | 25.96 | -$180.97 million | ($0.83) | -10.04 |
| Tango Therapeutics | $37.04 million | 18.71 | -$58.24 million | ($1.15) | -6.83 |
Tango Therapeutics has lower revenue, but higher earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
40.4% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.3% of Tango Therapeutics shares are owned by institutional investors. 3.7% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.Volatility and Risk
Aurinia Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and price targets for Aurinia Pharmaceuticals and Tango Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurinia Pharmaceuticals | 0 | 1 | 4 | 0 | 2.80 |
| Tango Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Aurinia Pharmaceuticals presently has a consensus price target of $12.50, indicating a potential upside of 50.06%. Tango Therapeutics has a consensus price target of $21.00, indicating a potential upside of 167.18%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than Aurinia Pharmaceuticals.
Profitability
This table compares Aurinia Pharmaceuticals and Tango Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aurinia Pharmaceuticals | -89.50% | -26.03% | -22.85% |
| Tango Therapeutics | -418.63% | -32.72% | -21.48% |
Summary
Tango Therapeutics beats Aurinia Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Aurinia Pharmaceuticals
(Get Rating)
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
About Tango Therapeutics
(Get Rating)
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) and Tango Therapeutics (NASDAQ:TNGX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.
金色醫藥(納斯達克：AUPH-GET評級)和探戈治療(納斯達克：TNGX-GET評級)都是小盤醫療公司，但哪一家是優勢投資？我們將根據這兩家公司的風險、收益、盈利能力、股息、分析師建議、估值和機構所有權的強弱對它們進行比較。
Earnings & Valuation
收益與估值
This table compares Aurinia Pharmaceuticals and Tango Therapeutics' top-line revenue, earnings per share and valuation.
此表比較了aurinia製藥公司和Tango治療公司的營收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aurinia Pharmaceuticals | $45.60 million | 25.96 | -$180.97 million | ($0.83) | -10.04 |
| Tango Therapeutics | $37.04 million | 18.71 | -$58.24 million | ($1.15) | -6.83 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 金銀花製藥 | 4,560萬美元 | 25.96 | -1.8097億美元 | ($0.83) | -10.04 |
| 探戈治療學 | 3704萬美元 | 18.71 | -5824萬美元 | ($1.15) | -6.83 |
Tango Therapeutics has lower revenue, but higher earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
探戈治療公司的收入低於金色製藥公司，但收益高於金色製藥公司。Auinia PharmPharmticals的市盈率低於Tango治療公司，這表明它目前是兩隻股票中更負擔得起的一隻。
Institutional & Insider Ownership
機構與內部人持股
Volatility and Risk
波動性和風險
Aurinia Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.
Aurinia PharmPharmticals的貝塔係數為0.87，表明其股價的波動性比標準普爾500指數低13%。相比之下，Tango Treeutics的貝塔係數為1.78，這表明其股價的波動性比標準普爾500指數高78%。
Analyst Recommendations
分析師建議
This is a summary of recent ratings and price targets for Aurinia Pharmaceuticals and Tango Therapeutics, as provided by MarketBeat.
這是MarketBeat提供的Auinia製藥公司和Tango治療公司最近的評級和目標價摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurinia Pharmaceuticals | 0 | 1 | 4 | 0 | 2.80 |
| Tango Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 金銀花製藥 | 0 | 1 | 4 | 0 | 2.80 |
| 探戈治療學 | 0 | 0 | 1 | 0 | 3.00 |
Aurinia Pharmaceuticals presently has a consensus price target of $12.50, indicating a potential upside of 50.06%. Tango Therapeutics has a consensus price target of $21.00, indicating a potential upside of 167.18%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than Aurinia Pharmaceuticals.
Auinia PharmPharmticals目前的共識目標價為12.50美元，表明潛在漲幅為50.06%。探戈治療公司的一致目標價為2100美元，表明潛在的上漲幅度為167.18。鑑於Tango治療公司更強的共識評級和更高的可能上行空間，分析人士顯然認為Tango治療公司比Auinia製藥公司更有利。
Profitability
盈利能力
This table compares Aurinia Pharmaceuticals and Tango Therapeutics' net margins, return on equity and return on assets.
此表比較了aurinia製藥公司和Tango治療公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Aurinia Pharmaceuticals | -89.50% | -26.03% | -22.85% |
| Tango Therapeutics | -418.63% | -32.72% | -21.48% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 金銀花製藥 | -89.50% | -26.03% | -22.85% |
| 探戈治療學 | -418.63% | -32.72% | -21.48% |
Summary
摘要
Tango Therapeutics beats Aurinia Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
在兩隻股票之間的13個因素中，探戈治療公司有7個因素超過了金色製藥公司。
About Aurinia Pharmaceuticals
金色製藥公司簡介
(Get Rating)
(獲取評級)
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Auinia製藥公司是一家商業階段的生物製藥公司，專注於開發治療方法並將其商業化，以治療在美國和國際上未得到滿足的醫療需求的各種疾病。該公司提供LUPKYNIS用於治療成人活動性狼瘡性腎炎。它與大冢藥業有限公司有一項合作和許可協議，該公司總部設在加拿大維多利亞。
About Tango Therapeutics
關於探戈治療公司
(Get Rating)
(獲取評級)
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
探戈治療公司是一家生物技術公司，發現和開發治療癌症的藥物。它的主要項目是TNG908，一種合成的精氨酸甲基轉移酶5的致命小分子抑制劑，正在開發用於治療甲基硫代腺苷磷酸化酶缺失的癌症。該公司還開發了泛素特異性蛋白酶1，一種用於治療BRCA1或BRCA2突變癌症患者的抑制劑；以及針對STK11突變癌症的Target 3。探戈治療公司與吉利德科學公司進行了戰略合作，為癌症患者發現、開發一系列治療方法並將其商業化。該公司成立於2017年，總部設在馬薩諸塞州劍橋市。
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《金色醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對aurinia PharmPharmticals和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧